Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Marker molecule related to endometrial cancer and application thereof in diagnosis of endometrial cancer

A technology of endometrial cancer and diagnosis system, applied in the application field of diagnosis of endometrial cancer, can solve the problems of unpredictable recurrence, low sensitivity, and difficult screening of patients

Active Publication Date: 2021-10-12
BEIJING MEDINTELL BIOMED CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] At present, the most commonly used clinical detection markers are sugar chain antigen CA125 and human epididymis protein 4 (HE4). Among them, serum CA125 is helpful for monitoring clinical treatment effect for patients with extrauterine lesions, but for peritoneal inflammation or radiation injury CA125 may be abnormally elevated in patients with isolated vaginal metastases, but CA125 is not elevated in patients with isolated vaginal metastases, so recurrence cannot be predicted in the absence of other clinical findings. In addition, the sensitivity of CA125 and HE4 is low, and it is difficult to effectively screen patient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker molecule related to endometrial cancer and application thereof in diagnosis of endometrial cancer
  • Marker molecule related to endometrial cancer and application thereof in diagnosis of endometrial cancer
  • Marker molecule related to endometrial cancer and application thereof in diagnosis of endometrial cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1 Screening of biomarkers associated with endometrial cancer

[0073] 1. Screening method

[0074] (1) Screening data and preprocessing methods

[0075]In this example, the data for screening biomarkers related to endometrial cancer were downloaded from the GEO database and the TCGA database, respectively, and the public gene expression data and complete clinical data of endometrial cancer were searched with the keyword "endometrial cancer". Note, in which, the microarray data and clinical information of the GSE17025 dataset were downloaded from the GEO database as a training set, and the sample size was endometrial cancer group: control group=91:12; endometrial cancer RNA- The seq data and clinical information were used as the validation set, and the sample size was endometrial cancer group: control group=543:35;

[0076] Use fastp software double-end sequence automatic detection mode to process the raw data; the minimum N base number threshold is 5, the mini...

Embodiment 2

[0083] Example 2 Verifying and analyzing the diagnostic efficacy of the screened biomarkers

[0084] 1. Validation analysis method

[0085] The receiver operating curve (ROC) was drawn by the R package "pROC", and the biomarkers CDH1, RPS4X, CDH1 that were screened in Example 1 and showed significant differential expression between the control group and the endometrial cancer group were analyzed The AUC value, sensitivity and specificity of +RPS4X were used to judge its diagnostic performance for endometrial cancer. Among them, the gene expression (Log 2 expression) for evaluation and analysis, and the point corresponding to the largest Youden index was selected as its cutoff value, that is, the optimal division threshold was determined by the point with the largest Youden index; In terms of the diagnostic efficiency of cancer, first perform logistic regression analysis on the gene CDH1+RPS4X. In the logistic regression analysis, the independent variable is CDH1+RPS4X, and t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a marker molecule related to endometrial cancer and application thereof in diagnosis of the endometrial cancer. Biomarkers include CDH1 and RPS4X, and the CDH1 and RPS4X are combined to have good diagnosis efficiency, high sensitivity and high specificity on the endometrial cancer. The invention further provides a product and a diagnosis system for diagnosing the endometrial cancer.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and particularly relates to a marker molecule related to endometrial cancer and its application in diagnosing endometrial cancer. Background technique [0002] More than 90% of uterine cancers are endometrial carcinomas (EC), originating from the epithelium, most of the remaining uterine cancers are mesenchymal cancers, originating from the myometrium, and a few are endometrial stromal cancers 7% of all cancers, women have a 2.5% lifetime risk of developing endometrial cancer. EC is one of the three most common malignant tumors in the female reproductive system, accounting for 20%-30% of the malignant tumors of the female reproductive system. and gradually become younger. EC, as a malignant tumor with a high incidence of female reproductive system, is more common in postmenopausal women. [0003] In order to improve the quality of life of EC patients and improve the prognosis of patients, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886G01N33/57484G01N33/57488G01N33/57442C12Q2600/118C12Q2600/158
Inventor 杨承刚李雨晨刘乐凯
Owner BEIJING MEDINTELL BIOMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com